Avidity Biosciences (RNA) Share-based Compensation (2019 - 2025)
Historic Share-based Compensation for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to $19.0 million.
- Avidity Biosciences' Share-based Compensation rose 3499.86% to $19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.6 million, marking a year-over-year increase of 4572.73%. This contributed to the annual value of $51.4 million for FY2024, which is 3438.07% up from last year.
- Latest data reveals that Avidity Biosciences reported Share-based Compensation of $19.0 million as of Q3 2025, which was up 3499.86% from $17.7 million recorded in Q2 2025.
- In the past 5 years, Avidity Biosciences' Share-based Compensation ranged from a high of $19.0 million in Q3 2025 and a low of $3.7 million during Q1 2021
- Over the past 5 years, Avidity Biosciences' median Share-based Compensation value was $9.5 million (recorded in 2023), while the average stood at $9.9 million.
- Its Share-based Compensation has fluctuated over the past 5 years, first surged by 72427.62% in 2021, then surged by 1320.3% in 2024.
- Over the past 5 years, Avidity Biosciences' Share-based Compensation (Quarter) stood at $4.5 million in 2021, then soared by 61.8% to $7.3 million in 2022, then skyrocketed by 34.73% to $9.8 million in 2023, then soared by 43.76% to $14.2 million in 2024, then soared by 34.42% to $19.0 million in 2025.
- Its Share-based Compensation was $19.0 million in Q3 2025, compared to $17.7 million in Q2 2025 and $17.7 million in Q1 2025.